α1-抗糜蛋白酶A等位基因在阿尔茨海默病中无作用。
No effect of the alpha1-antichymotrypsin A allele in Alzheimer's disease.
作者信息
Didierjean O, Martinez M, Campion D, Hannequin D, Dubois B, Martin C, Puel M, Thomas Anterion C, Pasquier F, Moreau O, Babron M C, Penet C, Agid Y, Clerget-Darpoux F, Frebourg T, Brice A
机构信息
INSERM U 289, Hôpital de la Salpêtrière, Paris, France.
出版信息
J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):103-5. doi: 10.1136/jnnp.63.1.103.
The apolipoprotein E (ApoE)-epsilon4 allele is associated in a dose dependent manner to an increased risk for Alzheimer's disease. However, the ApoE-epsilon4 allele effect does not account for all patients with Alzheimer's disease, and the existence of other genetic risk factors has been postulated. Kamboh et al reported an association between Alzheimer's disease and the A allele of alpha1-antichymotrypsin (Aact) gene, which was not confirmed in a larger series more recently analysed. The ApoE and Aact genotypes were analysed in 314 patients with Alzheimer's disease and 173 healthy controls, confirming the dose dependent effect of the ApoE-epsilon4 allele. Nevertheless, even using odds ratios adjusted for age and sex, there was no significant effect of the Aact genotype on Alzheimer's disease or on the ApoE-epsilon4 allele associated risk for Alzheimer's disease.
载脂蛋白E（ApoE）-ε4等位基因与阿尔茨海默病风险增加呈剂量依赖性相关。然而，ApoE-ε4等位基因效应并不能解释所有阿尔茨海默病患者，因此推测存在其他遗传风险因素。坎博等人报告了阿尔茨海默病与α1-抗糜蛋白酶（Aact）基因A等位基因之间的关联，但最近在一个更大的系列分析中未得到证实。对314例阿尔茨海默病患者和173名健康对照者进行了ApoE和Aact基因型分析，证实了ApoE-ε4等位基因的剂量依赖性效应。然而，即使使用根据年龄和性别调整的优势比，Aact基因型对阿尔茨海默病或与ApoE-ε4等位基因相关的阿尔茨海默病风险也没有显著影响。
Zotero 插件